Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SK-09 SAD, MAD, and Food Effect Study in Healthy Adults
NCT07267026Phase 1Recruiting
- Sponsor
- Consun Pharmaceutical Group
- Start
- Dec 2025
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) comparing SK-09 with Placebo (2 arms). Primary endpoint: Safety Evaluation at 14 days. Started Dec 2025; status: recruiting.
02
Drugs
SK-09
03
Conditions
focal segmental glomerulosclerosis (FSGS)minimal change disease (MCD)
Beyond the preview
Go deeper on NCT07267026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07267026.